Research at Oslo University Hospital

 

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

 

Latest news

CCB researchers uncover novel mechanism of cellular metabolic control

 
First author Zhi Hong (left) and last author Camilla Raiborg
First author Zhi Hong (left) and last author Camilla Raiborg

A protein kinase complex known as mTORC1 is known to control cell growth by upregulating anabolic processes and downregulating catabolism in response to growth factors and nutritional cues such as amino acids. Because mTORC1 signalling is an important driver of cancer development, we need to understand how this signalling is regulated.
mTORC1 signalling occurs from lysosome membranes and is regulated by the lipid kinase PIK3C3 and its catalytic product, phosphatidylinositol 3-phosphate (PI3P), but the mechanism has remained unknown. Now, postdoc Zhi Hong and her co-workers in Camilla Raiborg’s project group at the Department of Molecular Cell Biology at the Institute for Cancer Research have discovered that PIK3C3 and PI3P control mTORC1 activation by regulating lysosome positioning.

 
 

Albumedix has signed research agreement with OUS and UiO on CIR research

 
Jan Terje Andersen
Jan Terje Andersen

In a press release, the pharmaceutical company Albumedix (Copenhagen, Denmark) has announced that it has signed a strategic research agreement with Oslo University Hospital and University of Oslo. The three organisations will work together to improve understanding of the interaction between bioengineered albumin variants and the neonatal Fc receptor (FcRn).
The research agreement is a result of a long collaboration between Albumedix scientists and Jan Terje Andersen and Inger Sandlie from CIR (UiO) and Department of Immunology (OUH).

 
 

Breast cancer research highlighted by the Norwegian Cancer Society:

New additional treatment for breast cancer patients

 
Olav Engebråten
Olav Engebråten

The Norwegian Cancer Society present research they support regularly, in a popular science form.
Olav Engebråten from the Department of Oncology at OUH has recently (October 10th) been interviewed about The NeoAva study he is leading - a clinical breast cancer study for patients with tumors more than 2.5 cm in diameter, where treatment with bevacizumab is involved - a substance (antibody) that binds and removes one of the factors (VEGF) excreted from the cancer cells that may stimulate the growth of blood vessels. The treatment can therefore prevent blood vessels from growing into the tumor tissue, and enhance the effect of the chemotherapy in the tumor.

 
 

Induced pluripotent stem cell research featured on Norwegian national news broadcast

 
Mathias Toft during NRK interview
Mathias Toft during NRK interview

A project involving the generation of induced pluripotent stem cells (iPSCs) from Norwegian patients with Parkinsons disease was recently featured on the evening news broadcast from the Norwegian Broadcasting Corporation (NRK). This project - a collaboration between neurologist Mathias Toft, project group leader at the Department of Neurology at Oslo University Hospital and Gareth Sullivan, group leader at the Stem Cell Center - aims to generate neurons from the patient-derived iPS cells and to investigate disease mechanisms in these. The project is an example of the activities supported by The Neuron Factory platform at the Norwegian Center for Stem Cell Research.

 
 

Scandic Holmenkollen Park, December 4-6, 2017:

The Norwegian Cancer symposium 2017 on Precision Medicine

 

We would like to extend an invitation to The Norwegian Cancer symposium 2017 on Precision Medicine
It will take place at Scandic Holmenkollen Park, December 4-6, 2017 in Oslo, Norway.

The meeting gathers leading national and international speakers in the field of precision medicine, and topics include the following:

  • Computational Cancer Genomics
  • Tumor Immunology and the microenvironment
  • Single cell analysis for disease trajectories and Liquid Biopsies
  • Monitoring cancer genetics in body fluids
  • Translational and clinical genomics
 
 

Tor Inge Tønnessen "Researcher of the Month" for September

 
T.I. Tønnessen
T.I. Tønnessen

The South-Eastern Norway Regional Health Authority (Helse Sør-Øst) has appointed Tor Inge Tønnessen from the Anaesthesia & Intensive Care Research Group at the Division of Emergencies and Critical Care at Oslo University Hospital as "Researcher of the month" for the month of September 2017.

 
 

Collaboration to identify novel biomarkers that can predict whether a patient will respond positively to pembrolizumab

 

The Norwegian bioinformatics company OncoImmunity and the Norwegian Cancer Genomics Consortium (NCGC) at Oslo University Hospital announce September 20th that they have entered into a collaboration with the American "Sarcoma Alliance for Research through Collaboration" (SARCtrials.org), to search for active neoantigens and related immune biomarker signatures of response in an American clinical trial on sarcoma patients treated with the PD1 immune checkpoint inhibitor pembrolizumab.

 
 

Jahre lecture Thursday September 14th

 
Inst. head H. Stenmark and Christer Betsholtz
Inst. head H. Stenmark and Christer Betsholtz

On Thursday September 14th The Institute for Cancer Research had the honour of hosting this year´s Jahre Prize winners for their lectures.
The lectures were by three of the leading scientists in the Nordic countries. The main prize winner (Christer Betsholtz) and one of the junior prize winners (Simon Bekker-Jensen) have their background in cancer research.

 
 

Anne-Lise Børresen-Dale appointed Commander of the Royal Norwegian St. Olavs Order

 

His Majesty The King has appointed Professor Emerita Anne-Lise Børresen-Dale as Commander of the Royal Norwegian St. Olavs Order for her outstanding efforts in medical research.
The decoration was be presented at an event in the Research Building at Radium Hospital in Oslo August 28.

 
 

ERC Starting Grant 2017 to Kyrre Eeg Emblem

 

The European Research Council (ERC) has awarded a Starting Grant 2017 to Kyrre Eeg Emblem from Department of Diagnostic Physics at the Divsion of Radiology & Nuclear Medicine. This is the seventh ERC Starting Grant awarded to Norway in the main panel Life Sciences (LS), and the first time Oslo University Hospital is the host institution.